Approval · Notice of Compliance 20050 · 2017

ADMELOG: Notice of Compliance 20050

Issued November 16, 2017

A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.

Notice number: 20050
Date: November 16, 2017
Company: Sanofi-Aventis Canada Inc.Toronto, Ontario, Canada
Product type: Biologic
Submission: New Drug Submission (NDS)
Submission class: Other

Products in this notice

Brand	DIN	Status today
ADMELOG	02469901	Marketed
ADMELOG	02469898	Marketed
ADMELOG	02469871	Marketed

Medicinal ingredients

INSULIN LISPRO 100 UNIT per VIAL
INSULIN LISPRO 100 UNIT per CART
INSULIN LISPRO 100 UNIT per PEN